Diabetes, Vol 49, Issue 12 2135-2141, Copyright © 2000 by American Diabetes Association

ARTICLES

Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes

MF Nielsen, B Nyholm, A Caumo, V Chandramouli, WC Schumann, C Cobelli, BR Landau, RA Rizza and O Schmitz
Department of Medicine M (Endocrinology and Diabetes), University Hospital of Aarhus, Denmark.

Impaired glucose effectiveness (i.e., a diminished ability of glucose per se to facilitate its own metabolism), increased gluconeogenesis, and endogenous glucose release are, together with insulin resistance and beta-cell abnormalities, established features of type 2 diabetes. To explore aspects of the pathophysiology behind type 2 diabetes, we assessed in a group of healthy people prone to develop type 2 diabetes (n = 23), namely first-degree relatives of type 2 diabetic patients (FDR), 1) endogenous glucose release and fasting gluconeogenesis measured using the 2H2O technique and 2) glucose effectiveness. The FDR group was insulin resistant when compared with an age-, sex-, and BMI-matched control group without a family history of type 2 diabetes (n = 14) (M value, clamp: 6.07 +/- 0.48 vs. 8.06 +/- 0.69 mg x kg(-1) lean body weight (lbw) x min(-1); P = 0.02). Fasting rates of gluconeogenesis (1.28 +/- 0.06 vs. 1.41 +/- 0.07 mg x kg(-1) lbw x min(-1); FDR vs. control subjects, P = 0.18) did not differ in the two groups and accounted for 53 +/- 2 and 60 +/- 3% of total endogenous glucose release. Glucose effectiveness was examined using a combined somatostatin and insulin infusion (0.17 vs. 0.14 mU x kg(-1) x min(-1), FDR vs. control subjects), the latter replacing serum insulin at near baseline levels. In addition, a 360-min labeled glucose infusion was given to simulate a prandial glucose profile. After glucose infusion, the integrated plasma glucose response above baseline (1,817 +/- 94 vs. 1,789 +/- 141 mmol/l per 6 h), the ability of glucose to simulate its own uptake (1.50 +/- 0.13 vs. 1.32 +/- 0.16 ml x kg(-1) lbw x min(-1)), and the ability of glucose per se to suppress endogenous glucose release did not differ between the FDR and control group. In conclusion, in contrast to overt type 2 diabetic patients, healthy people at high risk of developing type 2 diabetes are characterized by normal glucose effectiveness at near-basal insulinemia and normal fasting rates of gluconeogenesis.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Lerche, B. Brock, J. Rungby, H. E. Botker, N. Moller, A. Rodell, B. M. Bibby, J. J. Holst, O. Schmitz, and A. Gjedde Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans Diabetes, February 1, 2008; 57(2): 325 - 331. [Abstract] [Full Text] [PDF]

				S. M. Breckenridge, B. A. Cooperberg, A. M. Arbelaez, B. W. Patterson, and P. E. Cryer Glucagon, in Concert With Insulin, Supports the Postabsorptive Plasma Glucose Concentration in Humans Diabetes, October 1, 2007; 56(10): 2442 - 2448. [Abstract] [Full Text] [PDF]

				S. Forbes, S. Robinson, J. Dungu, V. Anyaoku, P. Bannister, D. Forster, S. Dissanayake, M. I McCarthy, I. A MacDonald, S. Venkatesan, et al. Sustained endogenous glucose production, diminished lipolysis and non-esterified fatty acid appearance and oxidation in non-obese women at high risk of type 2 diabetes Eur. J. Endocrinol., September 1, 2006; 155(3): 469 - 476. [Abstract] [Full Text] [PDF]

				M. F. Nielsen, A. Caumo, V. Chandramouli, W. C. Schumann, C. Cobelli, B. R. Landau, H. Vilstrup, R. A. Rizza, and O. Schmitz Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E102 - E110. [Abstract] [Full Text]

				R. C. Bonadonna, M. Stumvoll, A. Fritsche, M. Muggeo, H. Haring, E. Bonora, and T. W. van Haeften Altered Homeostatic Adaptation of First- and Second-Phase {beta}-Cell Secretion in the Offspring of Patients With Type 2 Diabetes: Studies With a Minimal Model to Assess {beta}-Cell Function Diabetes, February 1, 2003; 52(2): 470 - 480. [Abstract] [Full Text] [PDF]

				A. S. Lihn, T. Ostergard, B. Nyholm, S. B. Pedersen, B. Richelsen, and O. Schmitz Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients Am J Physiol Endocrinol Metab, February 1, 2003; 284(2): E443 - E448. [Abstract] [Full Text] [PDF]